AnaptysBio

ANAB

Market cap $543M

Overview Fund Activity

19.40 USD

-0.76

3.77%

At close Updated Sep 16, 4:00 PM EDT

Pre-market

After hours

19.40

0.00

0%

1 day

-3.77%

5 days

-12.61%

1 month

-3.1%

3 months

-18.83%

6 months

17.5%

Year to date

45.21%

1 year

-49.9%

5 years

23.25%

10 years

14.12%

About: AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Employees: 136

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

83% more call options, than puts

Call options by funds: $5.28M | Put options by funds: $2.89M

10% more capital invested

Capital invested by funds: $743M [Q1] → $816M (+$73.6M) [Q2]

4% less funds holding

Funds holding: 153 [Q1] → 147 (-6) [Q2]

5.11% less ownership

Funds ownership: 130.28% [Q1] → 125.17% (-5.11%) [Q2]

13% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 31

18% less repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 55

20% less funds holding in top 10

Funds holding in top 10: 5 [Q1] → 4 (-1) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$20

3% upside

Avg. target

$48

149% upside

High target

$80

312% upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

UBS Eliana Merle	$20	Neutral Maintained	12 Aug 2025
Wedbush Martin Fan	$45	Outperform Maintained	7 Aug 2025
JP Morgan Anupam Rama	$80	Overweight Maintained	24 Jul 2025

See Analyst Rankings

Financial journalist opinion

Anaptys Announces Participation in September Investor Conferences

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: Cantor Global Healthcare Conference 2025, New York, NY Format – Fireside chat and one-on-one investor meetings Date and Time – Wednesday, Sept. 3, 2025 at 8:00am ET / 5:00am PT 2025 Wells Fargo Healthcare Conference, Boston, MA Format – Fireside chat and one-on-one investor meetings Date and Time – Thursday, Sept.

Anaptys Announces Participation in September Investor Conferences

The Motley Fool

AnaptysBio (ANAB) Q2 Revenue Jumps 103%

AnaptysBio (ANAB) Q2 Revenue Jumps 103%

AnaptysBio (ANAB) Q2 Revenue Jumps 103%

Zacks Investment Research

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.34 per share versus the Zacks Consensus Estimate of a loss of $1.5. This compares to a loss of $1.71 per share a year ago.

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, 2025, and provided a business update.

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

AnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster Potential

Rosnilimab's strong Phase IIb RA data shows sustained efficacy and safety, positioning it as a potential blockbuster in a massive RA market. Despite JNJ's class setback, AnaptysBio offers significant upside, with fair value estimates nearly double its current market cap if RA approval is secured. Key risks include future cash needs, execution challenges, and tough competition, so I maintain a 2/5 conviction and keep ANAB in my speculative portfolio.

AnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster Potential

AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement

AnaptysBio, Inc.'s rosnilimab showed strong phase 2b results in moderate-to-severe RA, achieving key efficacy and safety endpoints, supporting its potential in a $20B U.S. market. Rosnilimab is also being evaluated in a phase 2 trial for moderate-to-severe ulcerative colitis, targeting a $15.8B global market, with data expected in Q4 2025. ANAB has sufficient cash for at least 12 months but may need to raise additional funds, potentially via an existing $100M ATM agreement.

AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

AnaptysBio, Inc. ANAB on Tuesday released updated data from the Phase 2b trial of rosnilimab, a PD-1 depleter and agonist, for rheumatoid arthritis.

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that investigational rosnilimab, a depleter and agonist targeting PD-1+ T cells, demonstrated a best-in-disease profile in patients with moderate-to-severe rheumatoid arthritis (RA). In the robust, global 424-patient Phase 2b trial, rosnilimab achieved JAK-like efficacy on multiple clinically meaningful measures, including low disease activity (LDA) and remission on the Clinical Disease Activity Index (CDAI), as well as ACR70 response, over a six-month period. Furthermore, responses were then durable for at least two months off drug. Rosnilimab was safe and well tolerated, particularly when compared to standard of care biologics or JAKs.

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor call and live webcast to review updated data from the global Phase 2b RENOIR clinical trial of investigational rosnilimab, a depleter and agonist targeting PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Tuesday, June 3, 2025, at 4:15pm ET / 1:15pm PT.

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

Zacks Investment Research

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates

AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.30. This compares to loss of $1.64 per share a year ago.

AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates

See News Rankings

Charts implemented using Lightweight Charts™